Gene Editing Race Between Editas and Vertex, CRISPR Heats Up

cafead

Administrator
Staff member
  • cafead   Jun 12, 2023 at 10:02: AM
via Friday, Editas Medicine unveiled early data from the RUBY and EdiTHAL trials, demonstrating the potential of its gene editor EDIT-301 in sickle cell disease and transfusion-dependent beta thalassemia.

article source
 

<